Literature DB >> 34023506

Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles.

Yoshihiko Kakiuchi1, Shinji Kuroda2, Nobuhiko Kanaya1, Kento Kumon1, Tomoko Tsumura1, Masashi Hashimoto1, Chiaki Yagi1, Ryoma Sugimoto1, Yuki Hamada1, Satoru Kikuchi3, Masahiko Nishizaki1, Shunsuke Kagawa3, Hiroshi Tazawa4, Yasuo Urata5, Toshiyoshi Fujiwara1.   

Abstract

Extracellular vesicles (EVs) play important roles in various intercellular communication processes. The abscopal effect is an interesting phenomenon in cancer treatment, in which immune activation is generally considered a main factor. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301), and occasionally observed therapeutic effects on distal tumors after local treatment in immunodeficient mice. In this study, we hypothesized that EVs may be involved in the abscopal effect of OBP-301. EVs isolated from the supernatant of HCT116 human colon carcinoma cells treated with OBP-301 were confirmed to contain OBP-301, and they showed cytotoxic activity (apoptosis and autophagy) similar to OBP-301. In bilateral subcutaneous HCT116 and CT26 tumor models, intratumoral administration of OBP-301 produced potent antitumor effects on tumors that were not directly treated with OBP-301, involving direct mediation by tumor-derived EVs containing OBP-301. This indicates that immune activation is not the main factor in this abscopal effect. Moreover, tumor-derived EVs exhibited high tumor tropism in orthotopic HCT116 rectal tumors, in which adenovirus E1A and adenovirus type 5 proteins were observed in metastatic liver tumors after localized rectal tumor treatment. In conclusion, local treatment with OBP-301 has the potential to produce abscopal effects via tumor-derived EVs.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  abscopal effect; drug delivery system; exosome; extracellular vesicles; local treatment; oncolytic adenovirus; systemic delivery

Mesh:

Year:  2021        PMID: 34023506      PMCID: PMC8530926          DOI: 10.1016/j.ymthe.2021.05.015

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  39 in total

1.  Whole body irradiation; radiobiology or medicine?

Authors:  R H MOLE
Journal:  Br J Radiol       Date:  1953-05       Impact factor: 3.039

Review 2.  Extracellular vesicles in cancer - implications for future improvements in cancer care.

Authors:  Rong Xu; Alin Rai; Maoshan Chen; Wittaya Suwakulsiri; David W Greening; Richard J Simpson
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

3.  Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.

Authors:  Yi Yang; Chia-Wei Li; Li-Chuan Chan; Yongkun Wei; Jung-Mao Hsu; Weiya Xia; Jong-Ho Cha; Junwei Hou; Jennifer L Hsu; Linlin Sun; Mien-Chie Hung
Journal:  Cell Res       Date:  2018-06-29       Impact factor: 25.617

Review 4.  Extracellular vesicles as biomarkers and therapeutic targets for cancer.

Authors:  Fumihiko Urabe; Nobuyoshi Kosaka; Kagenori Ito; Takahiro Kimura; Shin Egawa; Takahiro Ochiya
Journal:  Am J Physiol Cell Physiol       Date:  2019-11-06       Impact factor: 4.249

5.  Immunologic correlates of the abscopal effect in a patient with melanoma.

Authors:  Michael A Postow; Margaret K Callahan; Christopher A Barker; Yoshiya Yamada; Jianda Yuan; Shigehisa Kitano; Zhenyu Mu; Teresa Rasalan; Matthew Adamow; Erika Ritter; Christine Sedrak; Achim A Jungbluth; Ramon Chua; Arvin S Yang; Ruth-Ann Roman; Samuel Rosner; Brenna Benson; James P Allison; Alexander M Lesokhin; Sacha Gnjatic; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

6.  Exosome secretion is a key pathway for clearance of pathological TDP-43.

Authors:  Yohei Iguchi; Lara Eid; Martin Parent; Geneviève Soucy; Christine Bareil; Yuichi Riku; Kaori Kawai; Shinnosuke Takagi; Mari Yoshida; Masahisa Katsuno; Gen Sobue; Jean-Pierre Julien
Journal:  Brain       Date:  2016-09-27       Impact factor: 13.501

Review 7.  Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies.

Authors:  Oliver Kepp; Aurelien Marabelle; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2019-10-08       Impact factor: 66.675

8.  Tumour exosome integrins determine organotropic metastasis.

Authors:  Ayuko Hoshino; Bruno Costa-Silva; Tang-Long Shen; Goncalo Rodrigues; Ayako Hashimoto; Milica Tesic Mark; Henrik Molina; Shinji Kohsaka; Angela Di Giannatale; Sophia Ceder; Swarnima Singh; Caitlin Williams; Nadine Soplop; Kunihiro Uryu; Lindsay Pharmer; Tari King; Linda Bojmar; Alexander E Davies; Yonathan Ararso; Tuo Zhang; Haiying Zhang; Jonathan Hernandez; Joshua M Weiss; Vanessa D Dumont-Cole; Kimberly Kramer; Leonard H Wexler; Aru Narendran; Gary K Schwartz; John H Healey; Per Sandstrom; Knut Jørgen Labori; Elin H Kure; Paul M Grandgenett; Michael A Hollingsworth; Maria de Sousa; Sukhwinder Kaur; Maneesh Jain; Kavita Mallya; Surinder K Batra; William R Jarnagin; Mary S Brady; Oystein Fodstad; Volkmar Muller; Klaus Pantel; Andy J Minn; Mina J Bissell; Benjamin A Garcia; Yibin Kang; Vinagolu K Rajasekhar; Cyrus M Ghajar; Irina Matei; Hector Peinado; Jacqueline Bromberg; David Lyden
Journal:  Nature       Date:  2015-10-28       Impact factor: 49.962

9.  Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system.

Authors:  Katsuyuki Aoyama; Shinji Kuroda; Toshiaki Morihiro; Nobuhiko Kanaya; Tetsushi Kubota; Yoshihiko Kakiuchi; Satoru Kikuchi; Masahiko Nishizaki; Shunsuke Kagawa; Hiroshi Tazawa; Toshiyoshi Fujiwara
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

10.  Exosome mimicry by a HAVCR1-NPC1 pathway of endosomal fusion mediates hepatitis A virus infection.

Authors:  Maria Isabel Costafreda; Abdolrahim Abbasi; Hsinyi Lu; Gerardo Kaplan
Journal:  Nat Microbiol       Date:  2020-06-15       Impact factor: 17.745

View more
  6 in total

Review 1.  Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.

Authors:  Yaomei Tian; Daoyuan Xie; Li Yang
Journal:  Signal Transduct Target Ther       Date:  2022-04-06

Review 2.  Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies.

Authors:  Alessandro Allegra; Claudia Petrarca; Mario Di Gioacchino; Marco Casciaro; Caterina Musolino; Sebastiano Gangemi
Journal:  Cells       Date:  2022-03-27       Impact factor: 6.600

3.  The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.

Authors:  Moritz Klawitter; Ali El-Ayoubi; Jasmin Buch; Jakob Rüttinger; Maximilian Ehrenfeld; Eva Lichtenegger; Marcel A Krüger; Klaus Mantwill; Florestan J Koll; Markus C Kowarik; Per Sonne Holm; Ulrike Naumann
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

4.  Complexing the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T with Cationic Nanoparticles Enhances Viral Infection and Spread in Prostate and Pancreatic Cancer Models.

Authors:  Yang Kee Stella Man; Carmen Aguirre-Hernandez; Adrian Fernandez; Pilar Martin-Duque; Rebeca González-Pastor; Gunnel Halldén
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

Review 5.  Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.

Authors:  Zhongbing Qi; Xiangyu Long; Jiyan Liu; Ping Cheng
Journal:  Front Cell Neurosci       Date:  2022-09-09       Impact factor: 6.147

Review 6.  Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring.

Authors:  Wen Li; Ji-Bin Liu; Li-Kun Hou; Fei Yu; Jie Zhang; Wei Wu; Xiao-Mei Tang; Feng Sun; Hai-Min Lu; Jing Deng; Jie Bai; Juan Li; Chun-Yan Wu; Qin-Lu Lin; Zhong-Wei Lv; Gao-Ren Wang; Geng-Xi Jiang; Yu-Shui Ma; Da Fu
Journal:  Mol Cancer       Date:  2022-01-20       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.